In a filing, Axsome Therapeutics Inc revealed its Director Coleman Mark unloaded Company’s shares for reported $0.4 million on May 27 ’25. In the deal valued at $105.47 per share,3,750 shares were sold. As a result of this transaction, Coleman Mark now holds 50,387 shares worth roughly $5.55 million.
Then, Coleman Mark sold 3,750 shares, generating $387,862 in total proceeds. Upon selling the shares at $103.43, the Director now owns 46,637 shares.
Before that, Jacobson Mark L. sold 20,673 shares. Axsome Therapeutics Inc shares valued at $2,163,636 were divested by the Chief Operating Officer at a price of $104.66 per share. As a result of the transaction, Jacobson Mark L. now holds 5,783 shares, worth roughly $0.64 million.
Oppenheimer initiated its Axsome Therapeutics Inc [AXSM] rating to an Outperform in a research note published on June 03, 2025; the price target was $185. A number of analysts have revised their coverage, including Jefferies’s analysts, who began to cover the stock in early April with a ‘”a Buy”‘ rating. Deutsche Bank began covering AXSM with “Buy” recommendation on February 11, 2025. Mizuho maintained its rating on December 31, 2024. It rated AXSM as “an Outperform”.
Price Performance Review of AXSM
On Tuesday, Axsome Therapeutics Inc [NASDAQ:AXSM] saw its stock jump 2.28% to $110.11. Over the last five days, the stock has gained 5.90%. Axsome Therapeutics Inc shares have risen nearly 30.14% since the year began. Nevertheless, the stocks have risen 48.38% over the past one year. While a 52-week high of $139.13 was reached on 02/21/25, a 52-week low of $64.11 was recorded on 01/10/25. SMA at 50 days reached $107.90, while 200 days put it at $101.45.
Levels Of Support And Resistance For AXSM Stock
The 24-hour chart illustrates a support level at 108.46, which if violated will result in even more drops to 106.82. On the upside, there is a resistance level at 111.58. A further resistance level may holdings at 113.06. The Relative Strength Index (RSI) on the 14-day chart is 56.25, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 1.59, which suggests price will go up in the next trading period. Percent R suggests that price movement has been bullish at 12.99%. Stochastics %K at 65.60% indicates the stock is a holding.
How much short interest is there in Axsome Therapeutics Inc?
A steep rise in short interest was recorded in Axsome Therapeutics Inc stocks on 2025-05-15, dropping by -0.53 million shares to a total of 3.89 million shares. Yahoo Finance data shows the prior-month short interest on 2025-04-15 was 4.42 million shares. There was a decline of -13.75%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on September 03, 2024 when Wells Fargo began covering the stock and recommended ‘”an Overweight”‘ rating along with a $140 price target.
